Monoclonal antibody | |
---|---|
Type | Whole antibody |
Target | IL-22 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6408H9873N1706O2016S44 |
Molar mass | 144479.04 g·mol−1 |
(what is this?) (verify) |
Fezakinumab is a human monoclonal antibody against interleukin-22, [1] designed for the treatment of psoriasis and rheumatoid arthritis. [2]
Wyeth discovered and initially developed the drug, and clinical development continued after that company was acquired by Pfizer. Fezakinumab, in combination with methotrexate, completed a phase II trial in rheumatoid arthritis, [3] but data were not released. A small phase II trial of fezakinumab showed significant improvement in the Scoring Atopic Dermatitis (SCORAD) score for patients with severe atopic dermatitis. [4]